Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB
Links:
Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal…
https://acrabstracts.org/abstract/efficacy-and-safety-of-the-recombinant-anti-h…
17-11-2024